At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof John Gribben (Barts Cancer Institute, London, UK) and Prof Marek Trněný (Charles University Hospital, Prague, Czech Republic) discuss novel therapies and the future of chemotherapy-based regimens for the management of patients with relapsed or refractory mantle cell lymphoma.
This programme has been supported by sponsorship from Celgene.
